Novo Nordisk shares fall 5.5% after latest trial results for its next-generation weight loss drug

Core Insights - Novo Nordisk's next-generation weight-loss drug CagriSema has shown effectiveness, helping obese or overweight adult patients with type 2 diabetes lose 15.7% of their weight after 68 weeks [1] - Following the announcement, shares of Novo Nordisk experienced a decline of 5.52% at 11:10 a.m. London time [1]